Project Grant HT94252510890
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award supports research to cotarget the tumor microenvironment and revolutionize antibody-drug conjugate...
This Project Grant award of $1,270,020.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in developing personalized cancer vaccines targeting tumor heterogeneity and reprogramming the cold tumor micro-environment in kidney cancer. The award period runs from July 1, 2025 to June 30, 2029. MGH, a renowned non-profit academic medical center and a major...
This federal Project Grant award of $198,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop innovative approaches for the noninvasive detection of targetable mutations in non-small cell lung cancer brain metastases using radiosurgery, which aims to advance precision medicine for this patient population. The award was granted to The General Hospital Corporation, doing business as...
The Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $1,498,368 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a performance period from August 1, 2024 to July 31, 2027. The grant supports research to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, in order to optimize treatment of high-...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The Defense Health Agency awarded Massachusetts General Hospital a $582,732 project grant under the Military Medical Research and Development program to conduct research titled "Metabolic Targets to Overcome Chemoradiation Resistance in Genotype-Defined Non-Small Cell Lung Carcinoma." The CFDA number for the program is 12.420. Through this award spanning July 1, 2023 to June 30, 2025, MGH will investigate medical solutions for lung cancer treatment in military service members and the...
The U.S. Defense Health Agency awarded a $1,038,499.00 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the American Society for Clinical Pathology (ASCP), a non-profit organization. The grant, entitled "Enhancing Precision Oncology for Underserved Breast Cancer Patients through Deep Learning-Aided Histopathology Analysis", will fund research to develop advanced deep learning algorithms for improving breast cancer diagnostics and treatment,...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,644,309 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research focused on "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS". The grant, awarded on February 1, 2025, will support MGH's innovative research efforts to transform healthcare for military service members,...